 BERKELEY, Calif., Aug. 31, 2022 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq: CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the companys participation in the following investor conferences: 